US5344644A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Water-soluble composition for sustained-release
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1992-07-23
•
Granted: 1994-09-06
•
Expires: 2012-07-23
Abstract
Abstract A water soluble composition is described which comprises (a) a water soluble pharmacologically active peptide selected from the group consisting of cytokines or haematopoietic factors and (b) a sulfate group-containing acidic mucopolysaccharide and/or a desulfated modification of a naturally occurring sulfate group containing acidic mucopolysaccharide, and which brings about prolonged action of pharmacologically active peptides in a living body.
Inventors
- 👤 Yasutaka Igari
- 👤 Minoru Yamada
- 👤 Seiko Ishiguro
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 05:24
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/08; A61K38/09; A61K38/06; A61K38/066; A61K38/16; A61K38/17; A61K38/18; A61K38/1816; A61K38/19; A61K38/193; A61K38/20; A61K38/2013; A61K38/21; A61K38/212; A61K38/22; A61K38/28; A61K38/29; A61K38/43; A61K38/44; A61K38/446; A61K38/55; A61K38/57; A61K38/58; A61K47/00; A61K47/30; A61K47/36; A61K9/00; A61K9/0012; A61K9/0019
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
120 words
A water-soluble parenteral composition for injection which comprises (a) a water soluble pharmacologically active peptide selected from the group consisting of cytokines or hematopoietic factors, and (b) an alkali metal salt of a sulfate group-containing acidic mucopolysaccharide and/or a desulfated modification of a naturally occurring sulfate group-containing acidic mucopolysaccharide, wherein the weight ratio between (a) and (b) is about 0.001 to about 1:1, and wherein prior to injection, the tonicity and viscosity of the composition are adjusted by the addition of sterile water or sterile saline, to obtain a solution such that the viscosity of the solution is lower than 500 cP and the tonicity of the solution is from one-half to twice as high as that of physiological saline.
Claim 2
Dependent Claim
120 words
A water-soluble parenteral composition for injection which comprises (a) a water soluble pharmacologically active peptide selected from the group consisting of cytokines or hematopoietic factors, and (b) an alkali metal salt of a sulfate group-containing acidic mucopolysaccharide and/or a desulfated modification of a naturally occurring sulfate group-containing acidic mucopolysaccharide, wherein the weight ratio between (a) and (b) is about 0.001 to about 1:1, and wherein prior to injection, the tonicity and viscosity of the composition are adjusted by the addition of sterile water or sterile saline, to obtain a solution such that the viscosity of the solution is lower than 500 cP and the tonicity of the solution is from one-half to twice as high as that of physiological saline.
Claim 3
Dependent Claim
34 words
A water-soluble composition as claimed in claim 1, wherein the water-soluble pharmacologically active peptide is erythropoietin, granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interferons or interleukins.
Claim 4
Dependent Claim
37 words
A water-soluble composition as claimed in claim 1, wherein the sulfate group containing acidic mucopolysaccharide and/or the desulfated modification of a naturally occurring sulfate group-containing acidic mucopolysaccharide is chondroitin sulfate, heparan sulfate, keratan sulfate, chondroitin or heparan.
Claim 5
Dependent Claim
43 words
A water soluble composition as claimed in claim 1, further comprising a water-soluble protein selected from the group consisting of serum albumin, globulin, collagen and gelatin, wherein the weight ratio between the water-soluble protein and the mucopolysaccharide is from about 0.0001:1 to 100:1.
Claim 6
Dependent Claim
25 words
A water soluble composition as claimed in claim 1, wherein the viscosity of said solution of the water soluble composition is lower than 400 cP.
References Cited (Backward Citations)
US4609640A
Cited
US4447355A
Cited
EP0123291A2
Cited
JPS6043632A
Cited
US4585754A
Cited
US4857505A
Cited
EP0307097A2
Cited
EP0312208A1
Cited
US5024841A
Cited
JPH02126634A
Cited
US5013714A
Cited
WO1992000745A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-09-05 | 1998-03-07 | 1998-09-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-09-05 | 2002-03-07 | 2002-09-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-09-05 | 2006-03-07 | 2006-09-06 | $7700.00 | Window Closed / Lapsed |